2Hayes, JF, Marston, L, Walters, K, Geddes, JR, King, M, Osborn, DP.Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population-based UK cohort study using electronic health records. World Psychiatry 2016; 15: 53–8.
3Hayes, JF, Pitman, A, Marston, L, Walters, K, Geddes, JR, King, M, et al. Self-harm, unintentional injury, and suicide in bipolar disorder during maintenance mood stabilizer treatment: a UK population-based electronic health records study. JAMA Psychiatry 2016; 73: 630–7.
4Joas, E, Karanti, A, Song, J, Goodwin, GM, Lichtenstein, P, Landén, M.Pharmacological treatment and risk of psychiatric hospital admission in bipolar disorder. Br J Psychiatry 2017; 210: 197–202.
5Song, J, Sjölander, A, Joas, E, Bergen, SE, Runeson, B, Larsson, H, et al. Suicidal behavior during lithium and valproate treatment: a within-individual 8-year prospective study of 50,000 patients with bipolar disorder. Am J Psychiatry 2017; 174: 795–802.
6Lähteenvuo, M, Tanskanen, A, Taipale, H, Hoti, F, Vattulainen, P, Vieta, E, et al. Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder. JAMA Psychiatry 2018; 75: 347–55.
7Landén, M, Song, J.More efforts needed to clarify the effect of lithium in bipolar disorder: response to Terao et al. Am J Psychiatry 2017; 175: 80–1.
8Terao, T, Kanehisa, M, Shiotsuki, I, Ishii, N.Mixed features in bipolar I disorder and the effect of lithium on suicide. Am J Psychiatry 2017; 175: 80.
9Goodwin, G, Haddad, P, Ferrier, I, Aronson, J, Barnes, T, Cipriani, A, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2016; 30: 495–553.
10Malhi, GS, Bassett, D, Boyce, P, Bryant, R, Fitzgerald, PB, Fritz, K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49: 1087–206.
11Grunze, H, Vieta, E, Goodwin, GM, Bowden, C, Licht, RW, Möller, H, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry 2013; 14: 154–219.
12Grunze, H, Vieta, E, Goodwin, GM, Bowden, C, Licht, RW, Azorin, J, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry 2018; 19: 2–58.
13Öhlund, L, Ott, M, Oja, S, Bergqvist, M, Lundqvist, R, Sandlund, M, et al. Reasons for lithium discontinuation in men and women with bipolar disorder: a retrospective cohort study. BMC Psychiatry 2018; 18: 37.
14American Psychiatric Association. Desk Reference to the Diagnostic Criteria from DSM-5: Mini D5 (Swedish edition). Pilgrim Press AB, 2014.
15Posten, HO, Cheng, YH, Owen, DB.Robustness of the two-sample t-test under violations of the homogeneity of variance assumption. Commun Stat Theory Methods 1982; 11: 109–26.
16Baldessarini, RJ, Tondo, L, Viguera, AC.Discontinuing lithium maintenance treatment in bipolar disorders: risks and implications. Bipolar Disord 1999; 1: 17–24.
17Baldessarini, RJ, Tondo, L.Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: an overview. Clin Drug Investig 1998; 15: 337–51.
18Novick, DM, Swartz, HA, Frank, E.Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord 2010; 12: 1–9.
19Tondo, L, Pompili, M, Forte, A, Baldessarini, RJ.Suicide attempts in bipolar disorders: comprehensive review of 101 reports. Acta Psychiatr Scand 2016; 133: 174–186.
20Jawad, I, Watson, S, Haddad, PM, Talbot, PS, McAllister-Williams, RH.Medication nonadherence in bipolar disorder: a narrative review. Ther Adv Psychopharmacol 2018; 8: 349–63.
21Kraemer, S, Minarzyk, A, Eppendorfer, S, Henneges, C, Hundemer, H, Wilhelm, S, et al. Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study. BMC Psychiatry 2013; 13: 193.
22McCreadie, RG, McCormick, M, Morrison, DP.The impact of lithium in South-West Scotland. III. The discontinuation of lithium. Br J Psychiatry 1985; 146: 77–80.
23Scott, J, Pope, M.Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry 2002; 63: 384–90.
24Vieta, E, Azorin, J, Bauer, M, Frangou, S, Perugi, G, Martinez, G, et al. Psychiatrists’ perceptions of potential reasons for non-and partial adherence to medication: results of a survey in bipolar disorder from eight European countries. J Affect Disord 2012; 143: 125–30.
25Goodwin, GM.Recurrence of mania after lithium withdrawal: implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994; 164: 149–52.
26Kessing, LV, Hellmund, G, Geddes, JR, Goodwin, GM, Andersen, PK.Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011; 199: 57–63.
27Kessing, LV, Hellmund, G, Andersen, PK.An observational nationwide register based cohort study on lamotrigine versus lithium in bipolar disorder. J Psychopharmacology 2012; 26: 644–52.
28Kessing, LV, Bauer, M, Nolen, WA, Severus, E, Goodwin, GM, Geddes, J.Effectiveness of maintenance therapy of lithium vs other mood stabilizers in monotherapy and in combinations: a systematic review of evidence from observational studies. Bipolar Disord 2018; 20: 419–31.
29Garnham, J, Munro, A, Slaney, C, Macdougall, M, Passmore, M, Duffy, A, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord 2007; 104: 185–90.
30Simhandl, C, König, B, Amann, BL.A prospective 4-year naturalistic follow-up of treatment and outcome of 300 bipolar I and II patients. J Clin Psychiatry 2014; 75: 254–62.
31Tondo, L, Baldessarini, RJ, Floris, G.Long-term clinical effectiveness of lithium maintenance in types I and II bipolar disorders. Br J Psychiatry 2001; 178 (suppl 41): 184–90.
32Soares-Weiser, K, Vergel, YB, Beynon, S, Dunn, G, Barbieri, M, Duffy, S, et al. A Systematic Review and Economic Model of the Clinical Effectiveness and Cost-Effectiveness of Interventions for Preventing Relapse in People with Bipolar Disorder. NIHR Health Technology Assessment programme: Executive Summaries. NIHR Journals Library, 2007.
33Severus, E, Taylor, MJ, Sauer, C, Pfennig, A, Ritter, P, Bauer, M, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis. Int J Bipolar Disord 2014; 2: 15.
34Severus, E, Bauer, M, Geddes, J.Efficacy and effectiveness of lithium in the long-term treatment of bipolar disorders: an update 2018. Pharmacopsychiatry 2018; 52: 173–6.
35Kane, JM, Quitkin, FM, Rifkin, A, Ramos-Lorenzi, JR, Nayak, DD, Howard, A.Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982; 39: 1065–9.
36Amsterdam, JD, Shults, J.Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry 2010; 167: 792–800.
37Hartong, EG, Moleman, P, Hoogduin, CA, Broekman, TG, Nolen, WA, LitCar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64: 144–51.
38Greil, W, Ludwig-Mayerhofer, W, Erazo, N, Schöchlin, C, Schmidt, S, Engel, R, et al. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders–a randomised study. J Affect Disord 1997; 43: 151–61.
39Amsterdam, JD, Luo, L, Shults, J.Efficacy and mood conversion rate during long-term fluoxetine v. lithium monotherapy in rapid- and non-rapid-cycling bipolar II disorder. Br J Psychiatry 2013; 202: 301–6.
40Amsterdam, JD, Lorenzo-Luaces, L, Soeller, I, Li, SQ, Mao, JJ, DeRubeis, RJ.Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study. J Affect Disord 2015; 185: 31–7.
41Viktorin, A, Lichtenstein, P, Thase, ME, Larsson, H, Lundholm, C, Magnusson, PK, et al. The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer. Am J Psychiatry 2014; 171: 1067–73.
42Yatham, LN, Kennedy, SH, Parikh, SV, Schaffer, A, Bond, DJ, Frey, BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20: 97–170.
43Fountoulakis, KN, Grunze, H, Vieta, E, Young, A, Yatham, L, Blier, P, et al. The International College of Neuropsychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines. Int J Neuropsychopharmacol 2017; 20: 180–95.
44Takeshima, M.Treating mixed mania/hypomania: a review and synthesis of the evidence. CNS Spectr 2017; 22: 177–85.
45Plans, L, Barrot, C, Nieto, E, Rios, J, Schulze, TG, Papiol, S, et al. Association between completed suicide and bipolar disorder: a systematic review of the literature. J Affect Disord 2019; 242: 111–22.
46Pallaskorpi, S, Suominen, K, Ketokivi, M, Valtonen, H, Arvilommi, P, Mantere, O, et al. Incidence and predictors of suicide attempts in bipolar I and II disorders: a 5-year follow-up study. Bipolar Disord 2017; 19: 13–22.
47Tondo, L, Vázquez, GH, Pinna, M, Vaccotto, PA, Baldessarini, RJ.Characteristics of depressive and bipolar disorder patients with mixed features. Acta Psychiatr Scand 2018; 138: 243–52.
48Fiedorowicz, JG, Persons, JE, Assari, S, Ostacher, MJ, Zandi, P, Wang, PW, et al. Depressive symptoms carry an increased risk for suicidal ideation and behavior in bipolar disorder without any additional contribution of mixed symptoms. J Affect Disord 2019; 246: 775–82.
49Tondo, L, Baldessarini, RJ.Antisuicidal effects in mood disorders: are they unique to lithium? Pharmacopsychiatry 2018; 51: 177–88.
50Siskind, D, Reddel, T, MacCabe, JH, Kisely, S.The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study. Psychopharmacology (Berl) 2019; 236: 1931–5.
51Taylor, DM, Sparshatt, A, Amin, F, Osborne, I, Dzahini, O, Hughes, G, et al. Aripiprazole long-acting injection-a mirror image study of its effects on hospitalisation at one year. J Psychopharmacol 2017; 31: 1564–9.
52Baldassano, CF, Marangell, LB, Gyulai, L, Ghaemi, SN, Joffe, H, Kim, DR, et al. Gender differences in bipolar disorder: retrospective data from the first 500 STEP-BD participants. Bipolar Disord 2005; 7: 465–70.
53Karanti, A, Bobeck, C, Osterman, M, Kardell, M, Tidemalm, D, Runeson, B, et al. Gender differences in the treatment of patients with bipolar disorder: a study of 7354 patients. J Affect Disord 2015; 174: 303–9.
54Viguera, AC, Tondo, L, Baldessarini, RJ.Sex differences in response to lithium treatment. Am J Psychiatry 2000; 157: 1509–1.
55Sylvia, LG, Montana, RE, Deckersbach, T, Thase, ME, Tohen, M, Reilly-Harrington, N, et al. Poor quality of life and functioning in bipolar disorder. Int J Bipolar Disord 2017; 5: 10.